7/5/2023 | BK | Alkermes amends credit agreement to add SOFR as Libor replacement
|
3/1/2022 | BK | Moody's alters Alkermes view to stable
|
11/10/2021 | BK | Moody's eyes Alkermes for downgrade
|
3/9/2021 | BK | Market Commentary: Canada Goose frees to trade; Alkermes, Bad Boy Mowers, Apollo Commercial updates surface
|
3/9/2021 | CLHY | Market Commentary: Canada Goose frees to trade; Alkermes, Bad Boy Mowers, Apollo Commercial updates surface
|
3/9/2021 | BK | Alkermes finalizes $300 million term loan B at Libor plus 250 bps
|
3/8/2021 | BK | Moody's assigns Alkermes loan Ba3
|
3/2/2021 | BK | Market Commentary: Tronox breaks; WellSky, Corel updates emerge; Alkermes, Canada Goose, Ahlstrom release talk
|
3/2/2021 | CLHY | Market Commentary: Tronox breaks; WellSky, Corel updates emerge; Alkermes, Canada Goose, Ahlstrom release talk
|
3/2/2021 | BK | Alkermes talks $300 million term loan B at Libor plus 250-275 bps
|
3/1/2021 | BK | Market Commentary: CSC ServiceWorks, Applied Systems, TierPoint break; Tronox, CCRR Parent tweak deals
|
3/1/2021 | CLHY | Market Commentary: CSC ServiceWorks, Applied Systems, TierPoint break; Tronox, CCRR Parent tweak deals
|
3/1/2021 | BK | Alkermes readies launch of $300 million term loan B for Tuesday
|
3/6/2020 | CLHY | Market Commentary: Tosca Services, Duff & Phelps hit secondary; Alkermes pulls term loan B transaction
|
3/6/2020 | BK | Market Commentary: Tosca Services, Duff & Phelps hit secondary; Alkermes pulls term loan B transaction
|
3/6/2020 | BK | Alkermes withdraws $350 million term loan B from market
|
2/24/2020 | CLHY | Market Commentary: Astra changes surface; Messer Industries shelves repricing; Alkermes reveals price talk
|
2/24/2020 | BK | Market Commentary: Astra changes surface; Messer Industries shelves repricing; Alkermes reveals price talk
|
2/24/2020 | BK | S&P trims California Resources
|
2/24/2020 | BK | Moody's assigns Alkermes loan Ba3
|
2/24/2020 | BK | Alkermes launches $350 million term loan B at Libor plus 225 bps
|
2/21/2020 | CLHY | Market Commentary: Circor, Cast & Crew, Trade Me, HelpSystems deal updates surface; Grosvenor reveals talk
|
2/21/2020 | BK | Market Commentary: Circor, Cast & Crew, Trade Me, HelpSystems deal updates surface; Grosvenor reveals talk
|
2/21/2020 | BK | Alkermes readies launch of $350 million term loan B for Monday
|
2/21/2020 | BK | Alkermes readies loan lender call for Monday afternoon
|
3/23/2018 | BK | Market Commentary: EG Group, INAP, Mediacom, Pharmaceutical Product, Las Vegas Sands, Alkermes break
|
3/23/2018 | CLHY | Market Commentary: EG Group, INAP, Mediacom, Pharmaceutical Product, Las Vegas Sands, Alkermes break
|
3/20/2018 | BK | Moody’s rates Alkermes loan Ba3
|
3/16/2018 | BK | Market Commentary: Allison, Acadia, GVC, U.S. Security, Qdoba, Tank, Husky, Prestige, Engility and more break
|
3/16/2018 | BK | Alkermes launches $284.25 million term loan B at Libor plus 225 bps
|
3/15/2018 | BK | Market Commentary: Albea Beauty, EOC Group, Internet Brands, Four Seasons, Focus Financial free to trade
|
3/15/2018 | BK | Alkermes readies launch of $284.25 million term loan B for Friday
|
7/14/2017 | BK | Moody’s raises Alkermes to stable
|
10/7/2016 | CLHY | Market Commentary: Vivid Seats, First Data, Alkermes, PetSmart, Casella Waste, Micron Technology free to trade
|
10/7/2016 | BK | Market Commentary: Vivid Seats, First Data, Alkermes, PetSmart, Casella Waste, Micron Technology free to trade
|
10/7/2016 | BK | Alkermes finalizes $288 million term loan B-1 at Libor plus 275 bps
|
9/29/2016 | CLHY | Market Commentary: Secondary sees multiple loans break for trading; primary busy with deal changes, launches
|
9/29/2016 | BK | Market Commentary: Secondary sees multiple loans break for trading; primary busy with deal changes, launches
|
9/29/2016 | BKCV | Moody’s: Alkermes loan Ba3
|
9/29/2016 | BK | Alkermes launches $288 million term loan B-1 at Libor plus 275-300 bps
|
9/28/2016 | BK | Market Commentary: Nielsen Finance, Dunn Paper loans break; revisions announced on nine deals in primary market
|
9/28/2016 | BK | Alkermes to launch $288 million term loan B-1 extension on Thursday
|
1/21/2016 | BK | Moody’s changes Alkermes to negative
|
3/23/2015 | BK | Moody’s changes Alkermes view to stable
|
8/1/2013 | BK | Moody's lifts Alkermes loans
|
2/4/2013 | BK | Alkermes schedules credit facility lender call for Tuesday afternoon
|
9/25/2012 | BK | Market Commentary: Sheridan, ADS, Cannery, Allison break; Zayo down with repricing; TriZetto moves deadline
|
9/18/2012 | BK | Alkermes prices $375 million term loans atop tightened spread talk
|
9/18/2012 | BK | Market Commentary: Serta upsizes, slashes spread talk; Alkermes prices atop tightened talk; Truven brings repricing
|
9/14/2012 | BK | Alkermes restructures to add shorter-dated term loan, updates pricing
|
9/14/2012 | BK | Market Commentary: Cengage up with amend/extend chatter; Reynolds dips on paydown; FoxCo breaks above OID
|
9/10/2012 | BK | Market Commentary: Genesis HealthCare restructures; Alkermes sets talk; ConvaTec offer price emerges
|
9/10/2012 | BK | Alkermes launches $375 million term loan at Libor plus 375-400 bps
|
9/6/2012 | BK | Moody's rates Alkermes loan B1
|
9/5/2012 | BK | Alkermes plans to launch $375 million secured term loan on Monday
|
9/5/2012 | BK | Market Commentary: Burger King weakens with refinancing; DaVita gains; United Central, Nuveen reveal talk
|
10/7/2011 | BK | S&P: Alkermes loans BB, B
|
9/16/2011 | BK | Market Commentary: Avis Budget sees interest; Blackboard, Telx rework deals; Endurance International talk emerges
|
7/1/2011 | BK | Market Commentary: Alkermes first- and second-lien loans break; Pro Mach fills out; Ashland allocating soon
|
6/27/2011 | BK | Alkermes increases pricing on first-and second-lien term loans
|
6/27/2011 | BK | Market Commentary: SBA firms spread, breaks; Dole frees up; SRA, Alere, Lawson, Alkermes revisions emerge
|
6/21/2011 | BK | Market Commentary: Penn National, Rural/Metro break; Pre-Paid Legal restructures; Alkermes sets ticking fee
|
6/10/2011 | BK | Alkermes sets price talk on $450 million of first-, second-lien loans
|
6/9/2011 | CV | S&P: Alkermes loans BB, B
|
6/9/2011 | BK | S&P: Alkermes B+, loans BB, B
|
6/6/2011 | BK | Alkermes schedules Thursday launch for $450 million of term loans
|
6/6/2011 | BK | Market Commentary: Gibson, SemGroup break; Barbri, AutoTrader rework deals; NRG, Lawson, Embanet talk emerges
|
5/9/2011 | BK | Alkermes plans $450 million term loan for merger with Elan Drug
|
6/24/2010 | HYLMPV | RC Royalty Sub to redeem $38.5 million in 7% secured notes due 2018
|
5/28/2009 | HYPV | Alkermes buys back $18 million more of its 7% secured notes due 2012
|
11/6/2008 | HYPV | Alkermes buys back $60 million 7% notes in quarter
|
11/4/2008 | SS | Market Commentary: Amylin plunges 25.79%; Elliot cuts Epicor bid to $7.50; Merrill sets vote for Bank of America merger
|
11/6/2006 | BT | Alkermes on hold by Jefferies
|
11/3/2006 | BT | Merrill lowers Alkermes to neutral
|
10/18/2006 | BT | Merrill puts Alkermes at buy
|
8/9/2006 | BT | Alkermes kept at hold by Jefferies
|
8/9/2006 | BT | Merrill's buy rating for Alkermes unchanged
|
8/4/2006 | BT | Alkermes at buy by Merrill
|
8/1/2006 | BT | Alkermes kept at buy by Merrill
|
7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
7/19/2006 | BT | Merrill puts Alkermes at buy
|
6/16/2006 | BT | Alkermes rated at buy by Merrill
|
6/12/2006 | BT | Eli Lilly, Alkermes say inhaled insulin studies yield promising results
|
6/12/2006 | BT | Amylin, Lilly and Alkermes: study shows Byetta helps achieve glucose control in type 2 diabetes
|
6/5/2006 | BT | Eli Lilly, Alkermes complete enrollment for phase 3 safety study for inhaled insulin
|
5/22/2006 | BTCV | Alkermes to force conversion of 2.5% convertibles on June 15
|
5/19/2006 | BT | Alkermes reiterated at buy by Merrill
|
5/19/2006 | BT | Jefferies puts Alkermes on hold
|
5/19/2006 | BT | Market Commentary: Illumina gains after spot sale; Neurocrine, DOV mixed; Pozen pounded; Alkermes dips, settles higher
|
5/18/2006 | BT | Alkermes achieves first profitable year driven by 119% increase in total revenues
|
5/2/2006 | BT | Alkermes, Cephalon to make extended-release Vivitrol to treat alcoholism
|
4/26/2006 | BT | Eli Lilly, Alkermes start phase 3 study for inhaled insulin
|
4/18/2006 | BT | Merrill keeps Alkermes at buy
|
4/17/2006 | BT | Alkermes at hold by Jefferies
|
4/17/2006 | BT | Market Commentary: Invitrogen falls on lower sales forecast; Alkermes rises, dips; Targacept, Vanda gain; Dyax off
|
4/17/2006 | BT | Merrill has Alkermes at buy
|
4/13/2006 | BT | Alkermes, Cephalon receive FDA approval of Vivitrol for treatment of alcohol dependence
|
4/4/2006 | BT | Merrill puts Alkermes at buy
|
3/30/2006 | BT | Market Commentary: Amylin zooms to new high after follow-on; Seattle Genetics dips; Kosan declines 9% on spot sale
|
3/7/2006 | BT | Alkermes says FDA approved company's response to agency's approval letter on Vivitrol
|
2/17/2006 | BT | Alkermes responds to FDA questions on Vivitrol application
|
2/17/2006 | BT | Market Commentary: Cytyc shares, convertibles gain big; Alkermes slips on FDA news; NPS Pharma off amid uncertainty
|
2/17/2006 | CV | Market Commentary: Citadel gains on rumors of put-seeking hedge funds; Amgen's new issues continue week's climb
|
2/8/2006 | BT | Merrill puts Alkermes at buy
|
2/8/2006 | BT | Alkermes at hold by Jefferies
|
2/8/2006 | BT | Market Commentary: Pfizer news sparks buyout buzz; Immtech falls; Alkermes up; Icos off; Alexion higher; Oscient down
|
1/25/2006 | BT | Merrill keeps Alkermes at buy
|
1/20/2006 | BT | Market Commentary: DOR BioPharma stock jumps 15.6% on orBec news, equity line; Shire, Impax settle patent suit
|
1/20/2006 | CV | Market Commentary: Hutchinson hovers around par; Schlumberger surges; Ford sags, Oscient tumbles
|
1/12/2006 | BT | Merrill raises Alkermes target to $30
|
1/9/2006 | BT | Alkermes, Lilly to collaborate on inhaled treatment for osteoporosis
|
1/6/2006 | CV | Market Commentary: Convertibles market moves mostly in-line, dollar neutral; Best Buy, Cephalon gain; Affymetrix drops
|
1/3/2006 | BT | Market Commentary: Adams declines; Alkermes gains; Cephalon up; Indevus off; Wyeth up, Bradley off, ViroPharma rises
|
12/30/2005 | BT | Merrill maintains Alkermes at buy
|
12/30/2005 | BT | Alkermes still rated hold by Jefferies
|
12/30/2005 | BT | Alkermes, Cephalon gain preliminary approval for Vivitrol from FDA
|
12/14/2005 | BT | Merrill increases Alkermes price target to $24
|
11/30/2005 | BT | Market Commentary: Adams secondary launched; Isis off; Durect up; Inspire, BioCryst rocket up; Merck bonds weaker
|
11/4/2005 | BT | Merrill Lynch maintains Alkermes at buy
|
11/4/2005 | BT | Jefferies maintains Alkermes at hold
|
9/21/2005 | BT | Alkermes downgraded by Jefferies to hold
|
9/21/2005 | BT | Alkermes kept by Merrill Lynch at buy
|
9/21/2005 | BT | Market Commentary: Nektar, Cyberonics pitch converts; QLT spirals; Chiron players shift to 2.75s; Alkermes stumbles
|
9/20/2005 | BT | Market Commentary: Cyberonics convertible view mixed; Human Genome rises on update; Alkermes, Cephalon off on delay
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
8/23/2005 | BT | Alkermes retained by Merrill at buy
|
8/23/2005 | BT | Market Commentary: Amylin stock, convertibles zoom on drug data; OSI rebounds; Merck credit finds buyers; Wyeth sold off
|
8/23/2005 | CV | Market Commentary: Brocade convertibles move lower on call; Amylin gains outright but seen lower on a hedged basis
|
8/18/2005 | BT | Alkermes kept at buy at Merrill
|
8/10/2005 | BT | Alkermes price target raised by Jefferies
|
8/5/2005 | BT | Alkermes maintained by Merrill at buy
|
7/25/2005 | BT | Alkermes reiterated by Merrill at buy
|
6/24/2005 | CV | Market Commentary: Convertibles mostly extend losses a second day; biotechs waver, but some energy issues see more gains
|
6/24/2005 | BT | Market Commentary: HemoSense IPO delayed yet again; Cephalon off, Alkermes up on pact for alcoholism shot; Genentech up
|
2/7/2005 | CV | Market Commentary: Southern Union, Protein Design launch; Pinnacle Airlines edges up, raises Northwest paper
|
2/3/2005 | CV | Market Commentary: Pinnacle Airlines ends at 101.625; Alkermes drops on earnings, deal; FEI up on earnings; Alamosa gains
|
2/3/2005 | HY | New Issue: Alkermes raises $145 million with private placement of 7% notes due 2018
|
12/31/2003 | CV | Alkermes says 98.4% of convertibles tendered, sells $60 million new notes
|
9/8/2003 | CV | Alkermes greenshoe exercised, raising convertibles to $125 million
|
8/19/2003 | CV | New Issue: Alkermes sells $100 million convertible to yield 2.5%, up 10%
|
8/19/2003 | CV | Market Commentary: InVision deal scrapped amid summer lull, officially citing adverse "market conditions"
|
8/18/2003 | CV | Alkermes $100 million overnighter talked to yield 2.0-2.5%, up 10-15%
|
8/18/2003 | CV | Market Commentary: Alkermes returns to convertibles market; InVision reslated deal sweetened once, then again
|
6/18/2003 | CV | Semtech calls 41/2% convertibles
|
1/8/2003 | CV | Market Commentary: Tyco dominates trading day, power issues surge on manipulation suit dismissal
|
1/7/2003 | CV | Market Commentary: Heavy trading on Tyco deal; InterMune dives, techs and telecoms soar, power mixed
|
1/7/2003 | CV | Market Commentary: Heavy trading on Tyco deal; InterMune dives, techs and telecoms soar, power mixed
|
12/20/2002 | CV | Comcast starts change-of-control tender on remaining $107.666 million convertibles due 2020
|
12/19/2002 | CV | Market Commentary: Market settles back into slow, holiday-like mode
|
12/17/2002 | CV | Deutsche: Alkermes exchange more appealing than Cell Therapeutics', but both likely to succeed
|
11/26/2002 | CV | Alkermes starts exchange for 3.75% convertibles
|
11/6/2002 | CV | Alkermes plans exchange offer for convertibles, to sell up to $50 million new securities
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
7/1/2002 | CV | Market Commentary: Strong sell-off hits biotechs, drugs; Tyco pressure eases slightly
|
4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|